In The News
High Court to hear designer’s trade mark fight with Katy Perry
Law firm left ‘boxing at shadows’ ahead of Hyundai, Kia class action fight
TeleChoice close to ‘minimal’ settlement in franchisee class action
ASIC sues Hollard Insurance over 3-year delay in resolving claim
Judge allows tweak to ratings suit against S&P ahead of trial
Hunt & Hunt NSW, Hicksons Lawyers to join forces
Lawyer sacked for allegedly chucking a sickie not unfairly dismissed: FWC
Trial pushed off in sprawling litigation over Greensill collapse
Judge wants more than ‘bland’ claim of defects in Hyundai, Kia class actions
Firm, funder set to take half of AIG settlement in Linchpin class action
Please login to bookmark Close

The High Court won’t hear Bayer’s appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company’s claim the decision has “profound” consequences for drug R&D.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au